Andreas Fibig: Thank you, Mike and thank you to everyone for joining us today. I will begin today's call by providing an overview of our first quarter results including a review of our performance by region and segment. I would also like to share with you an update regarding our efforts to integrate DuPont N&B business, which continues to progress well, following the completion of our transaction in February. Rustom will then provide a more detailed financial review of the business highlighting segment level business dynamics and performance and cover cash flow and leverage as well. IFF is off to a strong start in 2021, and I'm confident that the momentum we have built will continue for the remainder of the year and beyond.  Now beginning with slide 6, I would like to review our performance and notable developments in the first quarter. We achieved 3% and combined sales growth or 1% on currency neutral basis compared to the first quarter of 2020. Also, because of our change to a fiscal calendar, rather than a traditional 445 calendar, we have had less two days less in first quarter. If we were to normalize for that our combined currency neutral growth in the first quarter would also have been approximately 3%. And on a two year average basis to factor in our strong 7% year ago comparison growth would be strong at approximately 5%. 
Andreas Fibig: Thank you Rustom and thanks again to all for joining us today. I would like to wrap up today's call by first giving an enormous thank you to our 1000s of employees around the world who have worked tirelessly over the last quarter to successfully execute our business initiatives, deliver for our customers and achieve solid top and bottom line business results. All while making exceptional strides integrating and envy to the IFF family. It has truly been a busy quarter and we all have much to be proud of especially as this all was accomplished during a global pandemic. Looking beyond our solid Q1 financial results, I want to re emphasize the important first step that we took in tightening our business and optimizing our portfolio strategy by agreeing to diversify our food preparation business. By diversifying this non core business IFF will be more efficient organization with a great capacity to focus on growth and innovation across our key businesses, ultimately generating greater value for our shareholders. As we enter Q2 together, we're confident that we have the right team and the right structures in place to ensure that our newly combined company will meet all financial operational goals. As I mentioned, we are targeting strong year-over-year financial improvements with accelerated test scores over the coming quarters backed by our commitment to delivering industry leading innovative products and services to our customers around the world. And as Rustom stated, we are pleased that we have started Q2 strong and optimistic that our full second quarter sales growth should be in a highest single digit range. I'm tremendously proud of all we have accomplished and I firmly believe that the best is yet to come by taking each and every learning from the N&B integration process to create a stronger, more agile and diversified company that defines the future of our industry and showcase what it means to be a leading ingredients and solutions partner.  With that I would like to open the call for questions. Thank you.
Andreas Fibig: Yes. Thank you Mike for the question. Yes, first of all I think that we really expect that the growth will accelerate over the course of the year. And that's driven as Rustom said as well was a good start into the second quarter, which was actually the first quarter was our toughest comparison. So that's the reason why we raised our sales expectations for the year. I think that's important. So now coming to the different parts of the business. I would say first of all we see if you look at the scent business unit, the real good recovery on fine fragrances which is really fantastic in the first quarter and also starting the second quarter which is good. We see still a great growth on cosmetic actives. So that's basically super important for us as well and the consumer fragrances stay on elevated level. If you go to the health and bioscience business, you see a couple of elements. You see that health and the conscious and food enzyme business should grow mid single digits. And you will see a recovery of the microbial control business, which was very much hurt by the situation last year. So that's important as well. And then on the Nourish side, very solid performance on taste, in particular, the legacy flavors doing very well. But on the new parts, protein solutions, via alternative proteins are doing going very well. And then you will see a turnaround in the food service as well in the countries and economies are opening up. And that's probably a general remark. We have seen good growth as you've seen in the presentation and most of the regions but in Europe, and Europe will turn around as soon as these economies are opening up after the pandemic as well. So I hope, Mike, that gives you a bit more color here.
Andreas Fibig: So let me start with the last question first. I think you are basically named all the companies which are relevant for us, maybe you should put carry in the mix as well, in particular for food service and some of the ingredients. And then you have actually a very nice peer group together. So what we want to do on the midterm is actually what we are doing, we have done completely a strategic assessment of all the categories where we believe that we have gross and margin potential. We certainly will emphasize in terms of our resources behind these categories. Some of these categories are just for example, on health, like the probiotics business, for example, where we put good resources behind to make sure that we can outgrow the competition here. And I think if you look at the start of into the year it's 3% of gross, if you adjust for the days, and there was a very strong comparison with 7% in the last year. So we are actually quite happy with the start and we have seen some of the portfolio pieces are performing very well. Like the flavors business is coming well. You see it in the everything which is plant based and protein related, and we see some that's a turnaround as well. And I mentioned before when Mike Sison asked on the microbial control which is coming back. We see the food service business are coming back. These are all good signals that we own a really solid track now to accelerate our growth and that's the reason why we said we raised our expectation for the rest of the year. 
Andreas Fibig: Lucas thank you for the question. So the combined company budget for R&D is approximately $620 million is about 5.5% of our annual sales. And we are certainly a leader in terms of R&D within the industry. What we have done is we went through all the different categories and technologies and look where we can put actually the best R&D dollars behind. So weâ€™re vitalizing our investment towards the highest return opportunities. And that means that we spend actually a fair amount of money on health and bioscience. I think that's very-very important. So the biotech area is one of the main investment areas for example, probiotics, enzymes, and cultures just to name one. And then we have certainly a centralized R&D approach and we have probably at least half of it on the centralized R&D and the rest goes into application and application lapse. But as I said, the big piece of our investment goes into the biotech area, which I think is super important for our customers and certainly for the development of some of our technologies going forward. I hope that helps.
Andreas Fibig: Faiza, good question. And it ties very well with the R&D question previously. So certainly we are not just offering, let's say the flavors and fragrances. So we have now a much broader set of technologies and innovative solutions. So we can play with it. And that can first of all differentiators in the marketplace, but also can help to reduce costs. For example, on the legacy IFF side we can partner with our customers. We formulate allowing to reduce the cost for example we can use our modulation technology for that to reduce costs for sweeteners in their products. But also in terms of our new platforms we have now really the leading biotech platform. And that gives us really endless opportunities to use fermentation technology, reduce input costs, and basically create some of the ingredients via biotech pathways. So actually bringing everything together gives us a very synergistic approach to help our customers not just to find super innovative solutions which are helping them to win their own clients and customers but also reduce costs. I think we are in a very-very good spot and position here.
Andreas Fibig: Yes, Matt, thank you for the question on India. We're probably 1% to 5% of our business in India. Actually, the Q1 was up double digit. So it was a very good performance. And it's interesting that you're asking it because it's such a desperate situation in terms of the pandemic right now. So I talk on a regular basis with our country manager and we haven't seen any slowdown of the business which is kind of interesting, but we are cautious with India. So far we haven't seen any negative impact on the business. But we are cautious and the business has won about 5% of our total business. 
Andreas Fibig: Yes. Let me get started and then I hand it over to Rustom for the raw material part. So we see more demands coming in from all our customers which is really good. So new product development is happening. And we don't see it just with our big customers. We see it with some of the small customers coming back as well which is I think it's a good and excellent sign. And we see it in many of our categories, even on the fine fragrance side, which has shown actually very strong development in the first quarter, and a good start or excellent start into the second quarter as well. So short answer, yes, we see an uptick our second part of it, and we see it all with smaller customers as well. Rustom if you go on the raw material.
Andreas Fibig: I think that's an important point what Rustom was just saying, because we have now with the integration, good flexibility on the RSA side basically to buffer these developments. 
Andreas Fibig: Yes, let me, Jeff thank you for the questions. The magnitude of the divestitures for the non-core businesses might be around about 5% of sales growth. That's what we are targeting right now. And in terms of Europe I think what is really important that you see the COVID impact on Europe. And that's probably the biggest impact we see right now. Because the composition of the business has a lot of food service in, for example, we have at least up to end of last year fine fragrance was impacted because a lot of it comes out of Europe as well. And that was probably the main impact. And now with the hopefully opening up of the economies in Europe and increasing vaccination rates we expect actually a good turnaround on with our European business. And actually we have seen the first signs already in April which is really-really good for us. I hope it helps to answer the question here.
Andreas Fibig: Sure, absolutely. Iâ€™ll take the first one, Rustom takes the second one. So the first thing we are seeing in cross selling is that we had to first big win with a big customer. And it was actually a cross sell in between our scent business and our health and bioscience business. So it's a combination where basically we get something on the enzyme side, because we have good access through our scent business. So bigger customer, European global customer. And I think on the product side, as I said, it's in the detergent area, which I think is very-very good and very promising because we see a good pipeline. Now also on the food side coming in also for our Nourish division. So it's going actually very-very well. And I think we can make the 20 million we promised for this year, actually quite-quite nicely in 21. And now I hand it over to Rustom.
Andreas Fibig: Sure Lisa. Absolutely. If I look at the different categories here the good news is, if we look at our forecast actually almost all of the categories will see some growth going forward, which is actually a great situation where we are being in. I agree with you on the consumer fragrance side where we had double digit developments in the last year we might see a bit of a normalization, but we still expect good growth and maybe single digit growth in that very important category. Another category where we have very strong comparables is probiotics. You might have seen this for a couple of months, it was for legacy N&B double digit growth last year. So we will see a normalization here, but still grows in the mid single digit range going forward. So these are the two categories which I would call out all the others are looking actually quite strong going forward in terms of growth. 
Andreas Fibig: Yes. Let me take it and start with the second question first. It is basically tougher comparisons. That's what it is because last year or end of first quarter and into the second quarter, it was very-very-very strong, very double digit. And that was hard to, let's say, to make up this year. We have seen, let's say, in Q1, for example on the health and bioscience piece we did double digit growth. And as soon as that normalizes we will see good growth coming out of out of H&B as well because the underlying business is actually very-very good. And the demand is strong. On the pricing side on, it's basically a pass through as you were saying it's easier to raise prices compared with some of the legacy F&F businesses and so that the time like is not as long as it is for some of the F&F businesses. I hope that answers the question the first part.
Andreas Fibig: Yes. Thank you for the participation. Certainly a very busy and good quarter for us because it was the first two months as the combined company and you've seen lots of moving parts also in the external environment. But I believe IFF handled that well and I would like to thank the employees again for that first quarter and then and also we see actually, a positive sales development and expectations for the rest of the year. With that I wish you a productive end of day and talk to you soon. Thank you. 
Rustom Jilla: Thank you, Andreas. First, let me go a bit deeper into our consolidated financial results. In the first quarter IFF generated 2.5 billion in sales, a 3% combined year-over-year increase including foreign exchange benefits, or up 1% on a currency neutral basis, primarily led by strong performances in our scent and pharma solutions division. As you may recollect from 2021 onwards, we are applying prior year average FX rates to our currency or non-US dollar revenues to derive currency neutral growth rates. This is the more common practice and makes us more comparable to our competitors.
Rustom Jilla: Right. Adam its Rustom. Let me take that question. So we started 2021 expecting our inflation to be low single digits, okay, with some modest increases, mostly offset by cost declines. But since then we've seen some large increases in raw materials. We've talked about them soy, bean on a whole bunch of them. Also higher freight costs due to sharply increased rates, plus higher air freight volume in specific areas where we have strong demand in a couple of inventory and supply chain challenges. But in any case, to answer your last part of your question we do not expect raw material and logistics inflation combined to be in the mid single digits this year. And obviously this requires us to go back to our customers. 
Rustom Jilla: Yes. Absolutely. So we do expect negative pressure on our gross margin this year. And that's because it takes a stain to go back to our customers. So students have the additional pricing discussions and all the rest of it. So we do not expect to be able to in this fiscal year to be able to recover the full extent of the raw material increases that we're seeing and we envisage okay. However, I mean, we do have positives. We do have positives coming from FX coming through. We do have positives from higher sales volumes. And we do have the positives from lower RSA as a percentage of sales. So on a operating margin perspective that reduces the negative down quite a bit. And at the end of the day, your EBITDA, I mean, combined with our focus on everything we've talked about the cost reduction or the rest of it, we're confident that we can achieve our full year adjusted operating EBITDA goal on a combined basis, the dollars. 
Rustom Jilla: Yes, I would say that soy and locust bean kernels do standout as two of the largest in there. And the vegetable oil is much smaller and several of them. And then I mean, turpentine is something we have as well, but much smaller dimension. And of the last one that we mentioned, propylene glycol that one is fundamentally it was force majeure related and will work its way back.
Rustom Jilla: Thanks Andreas. Yes. There is no change really, I mean, we had never before actually specifically guided to the P&L ex-amount, we thought that would be more useful, because as people have pointed out to us that when doing the modeling, I mean, we are talking about our EPS, EBITDA, all the rest of that. So that's really what we did. I mean, if you look at 2020, to clarify, I mean, the adjusted P&L numbers that we had for the whole year was 17.5% and the P&L ex- 18.5 right. And so the number this year, we're going to add 21.5 is just like the roughly about 100 basis points and the difference between those two, and then the and then the rest of it is just the fact that an N&B came with a higher tax profile, which we had communicated and expected.
Rustom Jilla: No, look for the rest of the year, I wouldn't be looking working capital to improve the same way at all. I mean, we had a very-very strong first quarter. I mean, we had roughly an eight day improvement in working capital days and that was driven by HIF&F inventory. That legacy IFF inventory and legacy N&B payables driving performance. As we go forward in the year we'll actually be building inventory at legacy N&B to satisfy demand and lessen the strain on our supply chain and also, the raw material cost increases we're talking about are going to increase the dollars on hand. I mean, DSO pretty stable through the rest of the year. And so we haven't specifically forecast core working capital. But basically, by the end of the year, I would think we'd expect it to go up a little bit. And that's all factored in. We are still pretty much able to deliver the 1 billion of free cash flow that we have in mind for the year as well. And that's with the working capital with the CapEx with everything.
Rustom Jilla: Yes. Lauren hi. The 12 months versus 11 is a factor, of course, coming through the number. We expect slightly higher CapEx than we originally envisaged as we invest in the business integration capacity, normal run, maintenance, all the rest of that. We're also building as we said, a little bit more inventory than we expected to and in the legacy N&B end of the business, and so that's going to add as well. And fundamentally I mean, the rest of it is a strong EBITDA, and then the business just flows through. 
